Ken Griffin Keros Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 176,144 shares of KROS stock, worth $3.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

176,144

Previous 22,898 669.25%

Holding current value

$3.04 Million

Previous $305,000 813.44%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$13.34 - $16.05 $2.04 Million - $2.46 Million	153,246 Added 669.25%	176,144 $2.79 Million
Q2 2025 Aug 14, 2025	SELL	$9.55 - $15.11 $1.61 Million - $2.55 Million	-168,711 Reduced 88.05%	22,898 $305,000
Q1 2025 May 15, 2025	SELL	$10.15 - $16.1 $6.08 Million - $9.65 Million	-599,500 Reduced 75.78%	191,609 $1.95 Million
Q4 2024 Feb 14, 2025	BUY	$15.64 - $70.0 $1.35 Million - $6.03 Million	86,186 Added 12.23%	791,109 $12.5 Million
Q3 2024 Nov 14, 2024	BUY	$41.68 - $58.07 $12.3 Million - $17.1 Million	294,439 Added 71.73%	704,923 $40.9 Million

Q2 2024 Aug 14, 2024	SELL	$44.58 - $66.89 $1.77 Million - $2.66 Million	-39,794 Reduced 8.84%	410,484 $18.8 Million
Q1 2024 May 15, 2024	SELL	$41.26 - $70.48 $12.8 Million - $21.8 Million	-309,890 Reduced 40.77%	450,278 $29.8 Million
Q4 2023 Feb 14, 2024	BUY	$27.12 - $41.05 $9.63 Million - $14.6 Million	355,019 Added 87.63%	760,168 $30.2 Million
Q3 2023 Nov 14, 2023	BUY	$31.57 - $43.02 $2.44 Million - $3.33 Million	77,349 Added 23.6%	405,149 $12.9 Million
Q2 2023 Aug 14, 2023	SELL	$37.26 - $51.01 $1.63 Million - $2.23 Million	-43,683 Reduced 11.76%	327,800 $13.2 Million
Q1 2023 May 15, 2023	SELL	$41.44 - $59.32 $1.41 Million - $2.02 Million	-33,988 Reduced 8.38%	371,483 $15.9 Million
Q4 2022 Feb 14, 2023	SELL	$39.45 - $51.77 $892,990 - $1.17 Million	-22,636 Reduced 5.29%	405,471 $19.5 Million
Q3 2022 Nov 14, 2022	BUY	$27.8 - $40.12 $2.05 Million - $2.96 Million	73,753 Added 20.81%	428,107 $16.1 Million
Q2 2022 Aug 15, 2022	BUY	$26.03 - $67.04 $1.93 Million - $4.97 Million	74,193 Added 26.48%	354,354 $9.79 Million
Q1 2022 May 16, 2022	BUY	$42.12 - $59.36 $128,845 - $181,582	3,059 Added 1.1%	280,161 $15.2 Million
Q4 2021 Feb 14, 2022	BUY	$36.95 - $62.89 $102,610 - $174,645	2,777 Added 1.01%	277,102 $16.2 Million
Q3 2021 Nov 15, 2021	BUY	$29.27 - $43.71 $4.58 Million - $6.84 Million	156,377 Added 132.58%	274,325 $10.9 Million
Q2 2021 Aug 16, 2021	SELL	$42.4 - $70.11 $423,024 - $699,487	-9,977 Reduced 7.8%	117,948 $5.01 Million
Q1 2021 May 17, 2021	SELL	$54.0 - $75.28 $7.63 Million - $10.6 Million	-141,318 Reduced 52.49%	127,925 $7.87 Million
Q4 2020 Feb 16, 2021	BUY	$36.0 - $82.74 $9.69 Million - $22.3 Million	269,243 New	269,243 $19 Million
Q3 2020 Nov 16, 2020	SELL	$27.04 - $62.21 $4.25 Million - $9.79 Million	-157,333 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$20.08 - $40.39 $3.16 Million - $6.35 Million	157,333 New	157,333 $5.9 Million

Others Institutions Holding KROS

# of Institutions

169

Shares Held

35.4M

Call Options Held

574K

Put Options Held

325K

View Full List

About Keros Therapeutics, Inc.

Ticker KROS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,757,000
Market Cap $445M
Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...

More about KROS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account